NCT01606215View on ClinicalTrials.gov

Stem Cells in Rapidly Evolving Active Multiple Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Multiple Sclerosis
Interventions
DRUG

Mesenchymal stem cells

1.0-2.0 million cells/kg body weight

DRUG

Placebo

Placebo

Trial Locations (1)

W12 0NN

Imperial College Healthcare NHS Trust, London

All Listed Sponsors
lead

Imperial College London

OTHER

NCT01606215 - Stem Cells in Rapidly Evolving Active Multiple Sclerosis | Biotech Hunter | Biotech Hunter